New study pits two diabetes drugs Head-to-Head for better sugar control
NCT ID NCT06399835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two diabetes medications, enavogliflozin and pioglitazone, when added to standard metformin treatment. It includes 120 adults with type 2 diabetes whose blood sugar is not well controlled. The goal is to see which drug works better at lowering blood sugar and improving heart health markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?